NEW YORK (GenomeWeb News) — Illumina yesterday said third-quarter revenues bolted 82 percent and R&D spending rose 160 percent, though profits fell 10 percent.
Total receipts for the three months ended Sept. 30 increased to $97.5 million from $53.5 million year over year.
Product revenues leapt to $90 million from $46.9 million, while service and other revenue rose to $7.4 million from $6.4 million year over year.